Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

• Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress.

• The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis.

• Consistent with the previous top-line data, the most frequently reported adverse events were diarrhea and nausea, with no increase in the incidence of GI-related adverse events noted after the first 12 weeks of resmetirom treatment.

• Related: Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular Health.

• SVB Leerink views the presentations as incrementally de-risking for the program.

• In a separate presentation, Madrigal also highlighted new results from a cohort of 105 NASH patients with compensated cirrhosis treated with resmetirom in an open-label portion of MAESTRO NAFLD-1.

• Resmetirom showed encouraging signals of efficacy.

• SVB says that despite the limitations of this study, it views these results as encouraging regarding resmetirom's ability to impact a broad range of non-invasive measures positively.

• Ultimately, it views the histology results expected in 4Q from the MAESTRO-NASH study as an essential value-inflecting data catalyst for Madrigal shares.

• JMP says that the key catalyst for MDGL shares, and the NASH field, remains the biopsy data from the Phase 3 MAESTRO-NASH study, which is on track for 4Q22.

• The analyst keeps the Market Outperform rating and the price target of $170.00.

• Price Action: MDGL shares are down 9.24% at $74.74 during the market session on the last check Monday.

Latest Ratings for MDGL

Date	Firm	Action	From	To
Oct 2021	Jefferies	Initiates Coverage On		Buy
Aug 2021	HC Wainwright & Co.	Maintains		Buy
May 2021	Canaccord Genuity	Maintains		Buy

View More Analyst Ratings for MDGL

View the Latest Analyst Ratings

See more from Benzinga

• The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

• GSK Shares Encouraging Data From Chronic Hepatitis B Candidate

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.